Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, ...
12 hours ago
0
3
Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous. ...
Jun 25, 2026
0
7
A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer. The study shows that a combination of two well-studied classes ...
Jan 13, 2026
0
28
Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features ...
Oct 22, 2025
0
13
Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), ...
May 28, 2025
0
36
A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by researchers at City of Hope.
Apr 24, 2025
0
32
A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA-approved drug in the market—and ...
Mar 10, 2025
0
17
When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug ...
May 9, 2024
0
52
Researchers at the Center for Genomic Regulation in Barcelona, Spain, and the Wellcome Sanger Institute near Cambridge, UK, have comprehensively identified the allosteric control sites found in the protein KRAS. These are ...
Dec 18, 2023
0
47
A review paper titled "Targeting Ras with protein engineering" has been published in Oncotarget.
Nov 27, 2023
0
29
